PRODUCTS SERVICES COMPANY CONTACT FAQ

Search Dictionary Mobile

Login

J Brandt Selected Research

infliximab (Remicade)

09/2007	Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab.
02/2006	Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
12/2005	Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
10/2005	Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.
05/2005	Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
02/2005	Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
10/2004	[Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12]
08/2003	Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
04/2003	Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
11/2002	Infliximab in the treatment of active and severe ankylosing spondylitis.
04/2002	Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
12/2001	Infliximab treatment of severe ankylosing spondylitis: one-year followup.
06/2000	Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.

Articles by Research Topic

Disease

24	Ankylosing Spondylitis 09/2007 - 06/2000
4	Alzheimer Disease (Alzheimer's Disease) 05/2008 - 10/2000
4	Necrosis 12/2005 - 11/2000
2	Dementia (Dementias) 09/2001 - 02/2000
2	Prostatic Neoplasms (Prostate Cancer) 02/2000 - 01/2000
1	Back Pain (Backache) 09/2006
1	Rheumatic Diseases (Rheumatism) 12/2005
1	Peripheral Nervous System Diseases (PNS Diseases) 12/2005
1	Inflammation 12/2005
1	Neurocysticercosis 03/2003
1	Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis) 05/2002
1	Connective Tissue Diseases (Connective Tissue Disease) 01/2002
1	Syndrome 01/2002
1	Mixed Connective Tissue Disease (MCTD) 01/2002
1	Theileriasis 08/2001
1	Infection 08/2001

Drug/Important Bio-Agent (IBA)

13	infliximab (Remicade)FDA Link 09/2007 - 06/2000
6	TNFR-Fc fusion protein (etanercept)FDA Link 02/2006 - 06/2003
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2007 - 06/2000
3	Apolipoproteins E (ApoE)IBA 05/2008 - 04/2002
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 09/2006
1	RadiumIBA 05/2006
1	leflunomide (Arava)FDA LinkGeneric 12/2005
1	pamidronate (APD)FDA LinkGeneric 08/2003
1	Interferon-gamma (Interferon, gamma)IBA 06/2003
1	AntigensIBA 03/2003
1	Cathepsin B (B, Cathepsin)IBA 05/2002
1	Carbon MonoxideIBA 01/2002
1	Tetracycline (Achromycin)FDA LinkGeneric 08/2001
1	AntibodiesIBA 11/2000
1	Sertraline (Zoloft)FDA LinkGeneric 10/2000
1	Capromab Pendetide FDA Link 02/2000
1	PeptidesIBA 01/2000

Therapy/Procedure

2	Long-Term Care 09/2001 - 02/2000
1	Aftercare (After-Treatment) 03/2003
1	Baths 08/2001